HIV Drugs Prevent Type 2 Diabetes, May Be Path to New Therap
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A class of drugs long used to treat HIV and hepatitis B viral infections appears to prevent the development of diabetes in a substantial proportion of patients who take these agents, an analysis of multiple databases has shown.

"Nucleoside reverse-transcriptase inhibitors (NRTIs), drugs approved to treat HIV-1 and hepatitis B infections, also block inflammasome activation," researchers write in their article published recently in Nature Communications.

They showed that the adjusted risk of incident diabetes is 33% lower in patients with NRTI exposure. These data suggest the possibility of repurposing an approved class of drugs for prevention of diabetes.

The researchers made a small chemical modification to NRTIs that led to their developing a new class of drugs, which they have termed "kamuvudines." Kamuvudines are nontoxic derivatives of NRTIs, said researchers.

Researchers Screened Five Databases of more than 100,000 Patients. They analyzed information from five databases in which patients who had been exposed to an NRTI but who had not previously been diagnosed with type 2 diabetes were assessed for the subsequent development of diabetes over varying time intervals. In one, the Veterans Health Administration (VHA) database ? from the largest integrated healthcare system in the United States ? the analysis spanned a period of 17 years.

Of 79,744 patients with a confirmed diagnosis of HIV or hepatitis B in the VHA database, the risk for type 2 diabetes was reduced by 34% among NRTI users compared with nonusers after adjusting for potential confounders.

The reduction in diabetes risk was similar among HIV-positive and hepatitis B–positive patients.

These results were reaffirmed by further analyses of four other databases, the investigators report. One of these, the employer-based health insurance Truven database, had data on 23,634 patients who had been diagnosed with HIV or hepatitis B. After adjusting for potential confounders, NRTI users had a 39% lower risk of developing type 2 diabetes compared to nonusers.

"Collectively, among 128,861 patients with HIV-1 or hepatitis B, users of NRTIs had a 33% reduced hazard of developing type 2 diabetes," researchers emphasize.

Source: https://www.nature.com/articles/s41467-020-18528-z
Like
Comment
Share